# A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)

> **NCT04322604** · PHASE3 · COMPLETED · sponsor: **Allakos Inc.** · enrollment: 181 (actual)

## Conditions studied

- Eosinophilic Gastritis
- Eosinophilic Duodenitis

## Interventions

- **DRUG:** lirentelimab (AK002)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04322604
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2021-11-29
- **Final completion:** 2022-01-12
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2024-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04322604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04322604, "A Study to Assess AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis (Formerly Referred to as Eosinophilic Gastroenteritis)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04322604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*